Apath LLC is a New York-based company specializing in the development and licensing of innovative technologies for the screening and research of Hepatitis C Virus (HCV). With a strong focus on HCV-related intellectual property, Apath offers sublicensing opportunities, access to cutting-edge research tools, and expert virologist support to clients worldwide.
Through strategic partnerships with renowned institutions like The Rockefeller University and The University of Copenhagen, Apath has expanded its HCV technology portfolio, including full virus screening systems, replicon technologies, and highly permissive cell line technologies. Committed to providing exceptional development solutions, Apath aims to facilitate anti-HCV research and development for its global licensees.
Generated from the website